Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

OncLive - The European Commission has approved single-agent olaparib as a maintenance treatment for adult patients with germline BRCA1/2-mutant metastatic pancreatic adenocarcinoma who have not progressed...

OncLive - Investigators are working on a new generation of therapies that activate CD40, an immune checkpoint that helps promote an antitumor response by boosting T-cell–stimulatory...

AACR Annual Meeting | OncLive

posted 2 hours

Shared 0 times

OncLive - OncLive serves as a connection to everything oncology, including interviews and videos from thought leaders and cutting edge articles and...

OncLive - A panel of experts in chronic myeloid leukemia share insight on how to optimally approach treatment based on patient...

OncLive - Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive...

OncLive - Pembrolizumab plus axitinib continued to significantly improve efficacy over sunitinib in patients with previously untreated metastatic renal cell carcinoma, according to updated results from...

OncLive - The FDA has issued a complete response letter to Merck and Eisai stating that it will not approve the applications that are seeking the...

  • The @US_FDA has issued a response letter stating that they will not approve the accelerated approval of pembrolizumab/lenvatinib for HCC because the combo does not provide evidence that it offers a meaningful advantage over other options. #hpbcsm https://t.co/REZmaYZDyi https://t.co/REZmaYZDyi

OncLive - Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival...

OncLive - One of the major mysteries in treating patients with COVID-19 is the frequent development of blood clots that can subsequently damage their organs and...

Postow Presents Progress Made in Melanoma

posted 8 hours

Shared 0 times

OncLive - Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation...